BG85941A - Лекарствена форма с контролирано освобождаване и метод за получаването й - Google Patents

Лекарствена форма с контролирано освобождаване и метод за получаването й

Info

Publication number
BG85941A
BG85941A BG085941A BG8594188A BG85941A BG 85941 A BG85941 A BG 85941A BG 085941 A BG085941 A BG 085941A BG 8594188 A BG8594188 A BG 8594188A BG 85941 A BG85941 A BG 85941A
Authority
BG
Bulgaria
Prior art keywords
obtaining
controlled
release pharmaceutical
pharmaceutical form
substance
Prior art date
Application number
BG085941A
Other languages
English (en)
Other versions
BG60638B1 (bg
Inventor
Masayoshi Samejima
Kazuo Noda
Masao Kobayashi
Shigeyuki Ishikawa
Original Assignee
Tanabe Seiyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co., Ltd. filed Critical Tanabe Seiyaku Co., Ltd.
Publication of BG85941A publication Critical patent/BG85941A/bg
Publication of BG60638B1 publication Critical patent/BG60638B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Лекарствената форма се състои от водоразтворимо ядро, включващо веществото дилтиазем или дилтиаземхлорид, вътрешен обвиващ слой от етилцелулоза и хидрофобно вещество и външен обвиващ слой, съдържащ лекарственото вещество. Тази форма осигурява бързо повишаване на концентрацията на медикамента в кръвта, като поддържането й на високо ниво е за по-продължителен период от време. 9 претенции, 4 фигури
BG85941A 1987-11-06 1988-11-03 Лекарствена форма с контролирано освобождаване иметод за получаването й BG60638B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28118987 1987-11-06

Publications (2)

Publication Number Publication Date
BG85941A true BG85941A (bg) 1993-12-24
BG60638B1 BG60638B1 (bg) 1995-11-30

Family

ID=17635585

Family Applications (1)

Application Number Title Priority Date Filing Date
BG85941A BG60638B1 (bg) 1987-11-06 1988-11-03 Лекарствена форма с контролирано освобождаване иметод за получаването й

Country Status (24)

Country Link
US (1) US4963365A (bg)
EP (1) EP0315414B1 (bg)
KR (1) KR940002655B1 (bg)
CN (1) CN1035099C (bg)
AT (1) ATE68343T1 (bg)
AU (1) AU610275B2 (bg)
BG (1) BG60638B1 (bg)
CA (1) CA1331565C (bg)
DE (1) DE3865631D1 (bg)
DK (1) DK175249B1 (bg)
ES (1) ES2027013T3 (bg)
FI (1) FI96273C (bg)
FR (1) FR2622799B1 (bg)
GR (1) GR3002915T3 (bg)
HK (1) HK44593A (bg)
HU (1) HU201468B (bg)
IE (1) IE60785B1 (bg)
IL (1) IL88083A (bg)
NO (1) NO176233C (bg)
PH (1) PH25905A (bg)
PT (1) PT88945B (bg)
RU (1) RU1816213C (bg)
SG (1) SG15493G (bg)
ZA (1) ZA888147B (bg)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268182A (en) * 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
DK0386440T3 (da) * 1989-02-11 1992-09-14 Bayer Ag Lægemidler med kontrolleret afgivelse af virksomt stof
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
EP0416094B1 (en) * 1989-03-22 1996-10-23 PANG, Peter K. T. Parathyroid hypertensive factor
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
ES2073301T3 (es) * 1991-05-20 1995-08-01 Marion Laboratories Inc Composicion multi-capa de liberacion controlada.
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5492700A (en) * 1991-11-26 1996-02-20 Warner-Lambert Company Process and composition for the development of controlled release gemfibrozil dosage form
EP0571973B1 (en) * 1992-05-29 2000-02-02 Nikken Chemicals Co., Ltd. Slow-release sodium valproate tablets
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
AU4219497A (en) * 1996-09-13 1998-04-02 Shionogi & Co., Ltd. Sustained-release preparation utilizing thermal change and process for the production thereof
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
WO2000009133A1 (en) * 1998-08-10 2000-02-24 Asahi Kasei Kogyo Kabushiki Kaisha Sustained release oral preparations of fasudil hydrochloride
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
EP1385486A4 (en) * 2001-04-18 2006-05-17 Nostrum Pharmaceuticals Inc NEW COATING OF SLOW RELEASE PHARMACEUTICAL COMPOSITION
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CN1296046C (zh) * 2003-12-23 2007-01-24 广州市医药工业研究所 盐酸地尔硫䓬控释胶囊剂及其制备方法
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US8088414B2 (en) 2006-02-07 2012-01-03 Fmc Corporation Latex or pseudolatex compositions, coatings and coating processes
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) * 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) * 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) * 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US20120308662A1 (en) * 2011-06-01 2012-12-06 Nitto Denko Corporation Particulate preparation and method for producing the same
FR2996418B1 (fr) * 2012-10-09 2015-05-29 Seppic Sa Compositions alimentaires comprenant des capsules obtenues par coacervation ne mettant pas en œuvre de reticulant toxique
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1172087A (fr) * 1956-01-25 1959-02-05 Bellon Labor Sa Roger Perfectionnements concernant l'enrobage de préparations à effet retardé et à effet soutenu
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
IT1153487B (it) * 1982-04-15 1987-01-14 Prophin Lab Spa Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli
US4390406A (en) * 1982-07-23 1983-06-28 Allied Corporation Replaceable outer junction double junction reference electrode
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins

Also Published As

Publication number Publication date
DK175249B1 (da) 2004-07-19
RU1816213C (ru) 1993-05-15
NO176233B (no) 1994-11-21
DK618088D0 (da) 1988-11-04
FI96273B (fi) 1996-02-29
NO176233C (no) 1995-03-01
HK44593A (en) 1993-05-14
IE883246L (en) 1989-05-06
FI885101A0 (fi) 1988-11-04
CA1331565C (en) 1994-08-23
ES2027013T3 (es) 1992-05-16
PT88945A (pt) 1989-11-30
FR2622799B1 (fr) 1991-11-29
BG60638B1 (bg) 1995-11-30
CN1033007A (zh) 1989-05-24
DE3865631D1 (de) 1991-11-21
DK618088A (da) 1989-05-07
PH25905A (en) 1991-12-19
IE60785B1 (en) 1994-08-10
AU610275B2 (en) 1991-05-16
AU2472788A (en) 1989-05-11
PT88945B (pt) 1993-05-31
FR2622799A1 (fr) 1989-05-12
EP0315414B1 (en) 1991-10-16
SG15493G (en) 1993-04-16
KR940002655B1 (ko) 1994-03-28
EP0315414A1 (en) 1989-05-10
NO884947D0 (no) 1988-11-04
IL88083A (en) 1992-11-15
FI96273C (fi) 1996-06-10
NO884947L (no) 1989-05-08
FI885101A (fi) 1989-05-07
GR3002915T3 (en) 1993-01-25
HU201468B (en) 1990-11-28
HUT50624A (en) 1990-03-28
ZA888147B (en) 1990-06-27
IL88083A0 (en) 1989-06-30
US4963365A (en) 1990-10-16
KR890007720A (ko) 1989-07-05
CN1035099C (zh) 1997-06-11
ATE68343T1 (de) 1991-11-15

Similar Documents

Publication Publication Date Title
BG85941A (bg) Лекарствена форма с контролирано освобождаване и метод за получаването й
NO904754L (no) Kapsel for innkapsling av biologisk aktive materialer, fremgangsmaate for fremstilling av denne, samt anvendelse derav.
ATE74519T1 (de) Waessrige loesung von fettloeslichen wirkstoffen.
IT8122136A0 (it) Capsule contenenti un allergene eprocedimento per la loro preparazione.
SE8504720L (sv) Ny lekemedelsberedning
NO883667D0 (no) Kapsel for farmasoeytisk virksomme innholdsstoffer av en droge.
FI95653C (fi) Menetelmä lääkeaineen anto- ja/tai annostelumuodon valmistamiseksi
DK285690D0 (da) Farmaceutisk doseringsform til medicinsk behandling af fisk
SE8701479D0 (sv) Metod for inneslutning av biologiskt verksamma preparat samt anvendning derav
ES519737A0 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
DE68917324D1 (de) Methode zur Immobilisierung von physiologisch aktiven Substanzen.
BG50375A3 (bg) Желатинова капсула
BG44709A3 (bg) Метод за получаване на 9-хлор-1,5-бензотиазепинови производни
MA19731A1 (fr) Isomere levogyre de la mequitazine , son procede de praparation et medicaments le contenant .
OA07171A (fr) Spirothiazolidineone, son procédé de préparation et préparation pharmaceutique la contenant.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
MY103627A (en) A controlled release pharmaceutical dosage form and a process for preparing same.
FI883576A0 (fi) Kemiskt foerfarande foer framstaellning av farmaceutiskt aktiva foereningar.
NL185666C (nl) Farmaceutisch preparaat of voorwerp en geneeskrachtige verbindingen.
NO905386L (no) Farmasoeytisk doseringsform ved medisinering av fisk.